SeaStar Medical's Q4 revenue rises, net loss narrows

Overview

• U.S. organ failure therapy maker's Q4 revenue rose sharply yr/yr, driven by expanded hospital sales

• Net loss for Q4 narrowed compared to prior year due to reduced operating expenses

• Company completed key clinical trial milestones and improved balance sheet with increased capital

Outlook

• SeaStar Medical anticipates about $2 mln in net product revenue in 2026

• Company aims to add 15 top-ranked children’s medical centers for QUELIMMUNE in 2026

• SeaStar Medical expects to complete NEUTRALIZE-AKI pivotal trial enrollment by end-2026

Result Drivers

• HOSPITAL ADOPTION - Revenue growth driven by expanded sales of QUELIMMUNE therapy to additional top-rated children's hospitals

• CLINICAL TRIAL PROGRESS - Achieved over 50% enrollment in pivotal adult AKI trial and completed SAVE Registry enrollment, supporting future growth initiatives

• OPERATING COST REDUCTION - Lower research and development and general administrative expenses contributed to a narrower net loss

Company press release: ID:nGNX6ddN2K

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for SeaStar Medical Holding Corp is $9.00, about 301.8% above its March 24 closing price of $2.24

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.